Michele Bernasconi

8PUBLICATIONS
18CO-AUTHORS
Radiation therapyMolecular targetsMedical molecular engineering of nucleic acids and proteinsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 17, 2024
Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future.

Victoria Judith Morel, Jochen Rössler, Michele Bernasconi

|Nov 04, 2023
CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.

Andrea Timpanaro, Caroline Piccand, Dzhangar Dzhumashev

|Feb 11, 2023
Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.

Andrea Timpanaro, Caroline Piccand, Anne-Christine Uldry

|Oct 27, 2022
Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma.

Dzhangar Dzhumashev, Andrea Timpanaro, Safa Ali

|Oct 20, 2021
CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein-Barr virus genes.

Semjon Sidorov, Lara Fux, Katja Steiner

|Nov 13, 2020
Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma.

Nagjie Alijaj, Sandrine Moutel, Zelia L Gouveia

Pageof 2

Frequent Collaborators

2 joint publications

Jochen Rössler

1 joint publications

Sandrine Moutel

1 joint publications

Paola Luciani

1 joint publications

Beat W Schäfer